|
448 Products |
| 448 Products |
|
1070 Diseases |  |
113911 News |  |
| «12...3233343536373839404142...11171118» |
- | haloperidol / Generic mfg.
Journal: LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons. (Pubmed Central) - Jun 19, 2024
demonstrate that haloperidol mediated changes in the striatal indirect pathway neurons and circuits are linked to Parkinson's disease associated LRRK2. Inhibiting LRRK2 kinase activity ameliorates the motoric side effects of haloperidol, suggesting a potential approach to alleviating the unwanted side effects of antipsychotics.
- | clozapine / Generic mfg.
Journal: Exploring memory-related network via dorsal hippocampus suppression. (Pubmed Central) - Jun 19, 2024
Our results were cross-validated using two different chemogenetic actuators, clozapine (CLZ) and clozapine-N-oxide (CNO)...Our study, using a chemogenetics-rsfMRI- behavior approach in awake rats, elucidates a comprehensive framework of the extended memory-associated network. This knowledge offers a broader interpretation of memory processes, enhancing our understanding of the neural mechanisms behind memory function, particularly from a network perspective.
- | clozapine / Generic mfg.
Journal: Functional coupling between MC4R and Kir7.1 contributes to clozapine-induced hyperphagia. (Pubmed Central) - Jun 19, 2024
Deletion of Kir7.1 in Mc4r-Cre neurons prevents clozapine-induced weight gain, while treatment with a selective Kir7.1 blocker mitigates overeating in clozapine-fed mice. Our findings unveil a molecular pathway underlying the effect of APDs on feeding behavior and suggest its potential as a therapeutic target.
- | haloperidol / Generic mfg.
Journal: Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors. (Pubmed Central) - Jun 19, 2024
Interestingly, the cytotoxic potency of the novel compounds resembled that of the SR1 antagonist HAL rather than the SR2 agonist siramesine (SRM), indicating the potential role of SR1 antagonism in their mechanism of action. The further exploration of their structure-activity relationships and their evaluation in additional cancer cell lines will elucidate their therapeutic potential and may pave the way for the development of novel anticancer agents that target SRs.
- || Review, Journal: Selective Serotonin Reuptake Inhibitors and Symptoms of Depression in Patients on Chronic Hemodialysis: A Systematic Review. (Pubmed Central) - Jun 19, 2024
In one study, citalopram and psychological interventions were both effective in reducing the symptoms of depression and anxiety and, in another study, sertraline was modestly more effective than CBT at 12 weeks in reducing the symptoms of depression...SSRI administration, at the dosage used in the studies included in the present systematic review, seems safe in most hemodialysis patients. However, the paucity of studies and the limited number of patients included in the trials may suggest that further randomized, controlled studies are needed to determine if SSRIs may be used routinely in daily clinical practice in such a population.
- | metadoxine / Generic mfg.
Journal: Reduced Pharmacological Intervention of Prehospital Services for Acute Alcohol Intoxication during the COVID-19 Pandemic in A Large District of Southern Italy. (Pubmed Central) - Jun 19, 2024
Conclusions ES is the first and only out-of-hospital service encountered by numerous patients with alcohol-use disorders who refuse to be admitted to the ED. These patients should be directed by ES personnel to a multidisciplinary program to receive treatment for drinking, improve their quality of life, and reduce sanitation costs.
- | amitriptyline / Generic mfg., sulfasalazine / Generic mfg.
Preclinical, Journal: Atractylodes macrocephala Koidz Alleviates Symptoms in Zymosan-Induced Irritable Bowel Syndrome Mouse Model through TRPV1, NaV1.5, and NaV1.7 Channel Modulation. (Pubmed Central) - Jun 19, 2024
In addition, transient receptor potential (TRP) V1, voltage-gated Na+ (NaV) 1.5, and NaV1.7 channels were inhibited. (4) These results suggest that AMK may be a promising therapeutic candidate for IBS management through the regulation of ion channels.
- | citalopram / Generic mfg., simvastatin / Generic mfg.
Journal, Stroma: Ageing and Polypharmacy in Mesenchymal Stromal Cells: Metabolic Impact Assessed by Hyperspectral Imaging of Autofluorescence. (Pubmed Central) - Jun 19, 2024
This polypharmacy regimen may have a more profound impact on MSCs than ageing, and can simultaneously reduce optical redox ratio (ORR) and increase porphyrin levels. This has implications for the use of autologous MSCs for older patients with chronic disease.
- || Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Review, Journal: D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside. (Pubmed Central) - Jun 19, 2024
It is a D3-preferring D3-D2 partial agonist with the highest binding to the D3 receptors compared to all other antipsychotics. Based on the example of cariprazine, there are several key factors that are needed for a molecule to move from the researcher bench to the patients' bedside, such as targeting an unmet medical need, having a novel mechanism of action, and a smart implementation of development plans.
- | amitriptyline / Generic mfg.
Preclinical, Journal: Amitriptyline and cholecalciferol amend hippocampal histological structure and myelination during stress in Wistar rats via regulating miR200/BMP4/Olig-2 signaling. (Pubmed Central) - Jun 19, 2024
We also found a negative correlation between the expression of BMP4, its mRNA, miR200, and the immunoexpression of MBP and Olig-2 proteins. This work underscores the amelioration of the stress-induced behavioral changes, inhibition of miR200/BMP4 signaling, and enhancement of hippocampal myelination following chronic administration of either amitriptyline or cholecalciferol, though cholecalciferol seemed more effective in brain remyelination.
- | chlorpromazine / Generic mfg.
Journal: Persistent hiccups after acute COVID-19 successfully treated with chlorpromazine: a case report. (Pubmed Central) - Jun 19, 2024
Consequently, hiccups occurring in the post-acute COVID-19 period may not be attributable to COVID-19. This case has highlighted the need to consider post-acute COVID-19 in the differential diagnosis of persistent hiccup.
- | tianeptine / Generic mfg.
Journal: Non-targeted identification of tianeptine photodegradation products in water samples by UHPLC-QTOF MS/MS. (Pubmed Central) - Jun 19, 2024
In addition, a toxicity assessment of the photoproducts was performed by in silico method, being generally all TPs of comparable toxicity to the precursor except for TP1, and showing a similar persistence in the environment except for TP2 and TP6, while TP4 was the only TP predicted as mutagenic. The developed method was applied for the analysis of four river water samples.
- ||| Trulicity (dulaglutide) / Eli Lilly
Preclinical, Journal, Adverse events: Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model. (Pubmed Central) - Jun 19, 2024
GLP-1RAs represent a promising strategy and deserve thorough future research. Our findings underline the potential importance of lifestyle intervention in addition to GLP-1 RA treatment.
- | nefazodone / Generic mfg., trazodone ER / Generic mfg.
Journal: Allosteric Inhibition and Pharmacochaperoning of the Serotonin Transporter by the Antidepressant Drugs Trazodone and Nefazodone. (Pubmed Central) - Jun 19, 2024
Trazodone and nefazodone rescued a folding-deficient variant of the serotonin transporter. This finding demonstrates that folding defects of mutated solute carrier-6 family members can also be corrected by allosteric ligands.
- || venlafaxine / Generic mfg., clarithromycin / Generic mfg., paroxetine / Generic mfg.
PK/PD data, Journal: PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine. (Pubmed Central) - Jun 19, 2024
Consequently, the present model successfully captured the pharmacokinetic alterations of venlafaxine and its active metabolite according to CYP2D6 genetic polymorphism as well as the DDIs between venlafaxine and two CYP inhibitors. The present model can be used to predict the pharmacokinetics of venlafaxine and its active metabolite considering different races, ages, coadministered drugs, and CYP2D6 activity of individuals and it can contribute to individualized pharmacotherapy of venlafaxine.
- | trazodone ER / Generic mfg.
Journal: The Use of Trazodone for Insomnia and Other Sleep Disturbances. (Pubmed Central) - Jun 18, 2024
The present model can be used to predict the pharmacokinetics of venlafaxine and its active metabolite considering different races, ages, coadministered drugs, and CYP2D6 activity of individuals and it can contribute to individualized pharmacotherapy of venlafaxine. No abstract available
- || Qelbree (viloxazine) / Supernus Pharma, Knight Therap
Review, Journal: Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. (Pubmed Central) - Jun 18, 2024
Two others, clonidine ER and guanfacine ER, are only approved for children and adolescents in the US...Drugs in Phase 3 trials include centanafadine, solriamfetol, and L-threonic acid magnesium salt...Lack of individual drug response and tolerability are reasons many stop treatment. Development of new nonstimulants may offer hope for patients who need medication alternatives.
- | sertraline / Generic mfg., fluoxetine / Generic mfg., carbamazepine / Generic mfg.
Journal: The Tissue-Specific Eco-Exposome: Differential Pharmaceutical Bioaccumulation and Disposition in Fish among Trophic Positions. (Pubmed Central) - Jun 18, 2024
Caffeine and sucralose, two common effluent tracers, were quantitated at low micrograms per liter levels in surface water, while an anticonvulsant, carbamazepine, was observed at levels up to 37?ng/L. The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and sertraline and primary metabolites were detected in at least one tissue of all three species at low micrograms per kilogram concentrations..
- | sertraline / Generic mfg., paroxetine / Generic mfg.
Preclinical, Journal: The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta-cell mass and function in vitro. (Pubmed Central) - Jun 18, 2024
Our data demonstrate that sertraline and paroxetine act directly on beta cells to enhance glucose-stimulated insulin secretion and stimulate beta-cell mass expansion by increasing proliferation and decreasing apoptosis. These drugs are therefore likely to be appropriate for treating depression in people with type 2 diabetes.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Variations in prescribing patterns for acute and preventive migraine medications in young adults: A retrospective, observational study () - Jun 18, 2024 - Abstract #AHS2024AHS_432;
Ten acute medications were evaluated with statistically significant differences in prescription rates demonstrated in eletriptan (8.0% vs. 3.5%, p = 0.001) and frovatriptan (4.7% vs. 1.3%, p = 0.001). We demonstrate statistically significant differences in prescription rates of common acute and preventive migraine medications when analyzing by age group.
- Ubrelvy (ubrogepant) / AbbVie, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
The use of Lifestyle Redesign () - Jun 18, 2024 - Abstract #AHS2024AHS_429;
She was also prescribed Ubrelvy in 2021, but she did not find it as effective as sumatriptan...She started Botox in 2022 and PT in 2023 and considers it to be helpful. She had also started Zonisamide 100 mg in 2023 which improved migraine severity (6
- venlafaxine / Generic mfg.
Management of chronic daily headaches and refractory migraines with less commonly prescribed agent Venlafaxine () - Jun 18, 2024 - Abstract #AHS2024AHS_427;
The mechanism of action for medications used for the prevention of migraines includes inhibition of cortical excitation as well as restoration of nociceptive dysmodulation. There is evidence that some antidepressant drugs are beneficial in the prophylaxis of migraine.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Nurtec ODT (rimegepant ODT) / Pfizer
Combined use of rimegepant and eptinezumab for treatment of chronic migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_420;
The co-administration of gepants and CGRP targeted mAbs can be effective in reducing severity and frequency of chronic migraine headaches. Patient did not report any adverse side effects from the combined use of these medications.
- Xeomin (incobotulinumtoxinA) / Merz Pharma
A case of a painful post-traumatic trigeminal neuropathy after endoscopic sinus surgery treated with incobotulinumtoxinA injection (PPTTN) () - Jun 18, 2024 - Abstract #AHS2024AHS_415;
IncobotulinumtoxinA should be considered in the treatment of PPTTN if refractory to conservative treatment. More cases are needed to determine whether this treatment is feasible and effective.
- Zavzpret (zavegepant nasal spray) / Pfizer
Zavegepant for the acute treatment of cluster headache: A case series () - Jun 18, 2024 - Abstract #AHS2024AHS_412;
This case series aimed to suggest the efficacy of zavegepant as a possible potent therapeutic agent for the treatment of an acute CH attack. In the five cases demonstrated in this study, zavegepant provided significant and rapid onset relief of symptoms of attacks of CH.
- Which combination of comorbidity makes migraine treatment impossible? A graphical approach () - Jun 18, 2024 - Abstract #AHS2024AHS_411;
Despite the diverse comorbidities considered, no combination of abortive or prevention medications was found to be entirely contraindicated for migraine patients. However, cardiac comorbidities such as uncontrolled hypertension or hypotension, prior coronary artery disease, and heart failure could significantly limit the possibility of abortive and preventive treatments.
- dihydroergotamine mesylate injection / Generic mfg.
Treatment of pediatric migraine in the emergency department: The importance of timely medication administration and intravenous dihydroergotamine () - Jun 18, 2024 - Abstract #AHS2024AHS_409;
Pediatric headaches are a common reason for presentation to the ED. Migraine cocktails are an effective treatment option for ongoing pediatric headaches with 83% of all encounters discharging after migraine cocktails
- amitriptyline / Generic mfg., topiramate / Generic mfg.
The use of antiepileptic medications versus antidepressant medications for the management of chronic headaches in children: A retrospective cohort study () - Jun 18, 2024 - Abstract #AHS2024AHS_405;
Both tricyclic antidepressants and antiepileptic drugs are helpful in the management of chronic migraine in adolescents. This retrospective analysis failed to demonstrate the superiority of one class of drug over the other.
- dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
Subjects view use of STS101 favorably: subject impression data from the phase 3 open-label ASCEND study () - Jun 18, 2024 - Abstract #AHS2024AHS_399;
P3
Most subjects considered STS101 easy to use and indicated they would be likely to use the product if it were available. In comparison to their usual migraine medications, subjects indicated that STS101 worked faster and more consistently, and enabled them to more rapidly return to normal.
- dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
STS101 demonstrated long-term clinical benefit in the phase 3 open-label ASCEND study () - Jun 18, 2024 - Abstract #AHS2024AHS_398;
P3
Exploratory efficacy analyses in this long-term safety study show high rates of freedom from pain and MBS through 48 h post dose for STS101. These effects were consistent throughout 12 months of study showing that STS101 is a reliable and effective treatment of acute migraine headache attacks.
- dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
STS101 (dihydroergotamine nasal powder) shows pain relief in difficult to treat migraine attacks: Results from the phase 3 double-blind, randomized, placebo-controlled summit study () - Jun 18, 2024 - Abstract #AHS2024AHS_397;
P3
These effects were consistent throughout 12 months of study showing that STS101 is a reliable and effective treatment of acute migraine headache attacks. The results of the SUMMIT study show that STS101 demonstrated significant anti-migraine effects versus placebo on headache pain relief, including in difficult to treat migraine attacks such as migraine with allodynia, menstrually-related migraine, and migraine with severe impact.
- dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
STS101 (dihydroergotamine nasal powder) shows long duration anti-migraine benefit on baseline photophobia, phonophobia, and nausea: Results from the phase 3 double-blind, randomized, placebo-controlled SUMMIT study () - Jun 18, 2024 - Abstract #AHS2024AHS_396;
P3
The results of the SUMMIT study show that STS101 demonstrated significant anti-migraine effects versus placebo on headache pain relief, including in difficult to treat migraine attacks such as migraine with allodynia, menstrually-related migraine, and migraine with severe impact. The results of the SUMMIT study show that, similar to its effects on migraine headache pain and most bothersome headache-associated symptom, STS101 showed significant anti-migraine effects versus placebo on baseline photophobia, phonophobia, and nausea from 3 through 48 h post-dose.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Safety and effectiveness of a novel implantable neurostimulator in the prevention of resistant migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_391;
The observed reduction in migraine frequency and improved HRQoL highlight its potential as an effective preventive therapy for resistant migraine. These preliminary results warrant a larger-scale study to confirm the safety and efficacy of the system.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Qulipta (atogepant) / AbbVie
Real-world evidence of adding atogepant to onabotulinumtoxina for control of chronic migraine: A retrospective chart review () - Jun 18, 2024 - Abstract #AHS2024AHS_387;
This real-world pilot study of patients with CM demonstrated clinically meaningful treatment benefit in the reduction of headache days with onabotulinumtoxinA alone and additive benefits with co-administration of atogepant. Safety results were consistent with the known safety profiles of onabotulinumtoxinA and atogepant.
- Nurtec ODT (rimegepant ODT) / Pfizer
Real world analysis of clinical characteristics and treatment patterns for migraine patients newly initiating rimegepant in China pilot zone () - Jun 18, 2024 - Abstract #AHS2024AHS_384;
P
Similarly, the median rizatriptan used days were 2, and median rizatriptan tablets were 4. Migraine patients with greater disease severity were more likely to go to China pilot zone to use rimegepant and the use of rimgepant tended to reduce the proportion of patients using other acute and preventive medications while decreasing MMDs.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Qulipta (atogepant) / AbbVie
Prophylactic polytherapy for chronic migraine: a single-site "real world" study evaluating the safety, tolerability and potential efficacy resulting from the addition of atogepant to onabotulinumtoxinA () - Jun 18, 2024 - Abstract #AHS2024AHS_383;
In this open-label observational trial, adding atogepant 60 mg to the prophylactic regimen of CM patients receiving BotoxA was safe and well-tolerated. The combined therapies were potentially synergistic in almost two-thirds of patients who completed the treatment phase.
- memantine / Generic mfg.
Patient response to memantine as add-on preventive therapy for post-traumatic headache () - Jun 18, 2024 - Abstract #AHS2024AHS_379;
While these findings are preliminary and confounded by multimodal treatment approaches to headache management, they support memantine's potential efficacy in this context, meriting further controlled studies. FIGURE 1 Average numbers of headache days pre- and post-treatment in 8 patients who had improvement in the number of headache days after initiation of memantine therapy (p < 0.0001).
- Nurtec ODT (rimegepant ODT) / Pfizer
Monthly migraine days, tablet utilization associated with the real world use of rimegepant among Chinese adults () - Jun 18, 2024 - Abstract #AHS2024AHS_375;
P, P2/3, P
Rimegepant administered as needed (PRN) in patients with ?6 MMDs was proved to be associated with reduced MMDs and monthly tablet utilization in two long-term safety studies (BHV3000-201, NCT03266588; BHV3000-318, NCT05371652)...Eligible patients with less than one dose of rimegepant, or treated with CGRP monoclonal antibodies or OnabotulinumtoxinA during 3 months of follow-up were excluded from this analysis... In this real-world analysis, rimegepant (PRN) can decrease the MMDs as early as first month and continued throughout the 3 months, and the number of rimegepant tablets administered/month also gradually declined during the treatment of 3 months.
- dihydroergotamine intranasal (STS101) / Shin Nippon Biomedical Labs
Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study () - Jun 18, 2024 - Abstract #AHS2024AHS_369;
P3
TEAEs were mostly local, mild, and transient with a low discontinuation rate. Table 1: Most Common TEAEs (PTs Reported by ?5% of Subjects)
- Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo, Organon
Efficacy of lasmiditan used as a secondary treatment for migraine attacks after unsuccessful treatment with a triptan () - Jun 18, 2024 - Abstract #AHS2024AHS_354;
Table 1: Most Common TEAEs (PTs Reported by ?5% of Subjects) Based on the results obtained, we would recommend a step care treatment, consisting of initial triptan followed by lasmiditan if needed, for treating the symptoms of migraines.
- Elyxyb (celecoxib) / Dr. Reddy's, Collegium Pharma, Sorrento
Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post hoc analysis of 2 phase 3 randomized clinical trials () - Jun 18, 2024 - Abstract #AHS2024AHS_352;
P3
TABLE 1 Demographics of the triptan insufficient responder and triptan responder subgroups. FIGURE 1 Efficacy of celecoxib oral solution 120 mg in triptan insufficient responders and triptan responders.
- meloxicam/rizatriptan (AXS-07) / Axsome Therap
Combined efficacy and safety of AXS-07 (MOSEIC(TM) meloxicam and rizatriptan) in two phase 3 clinical trials () - Jun 18, 2024 - Abstract #AHS2024AHS_337;
FIGURE 1 Efficacy of celecoxib oral solution 120 mg in triptan insufficient responders and triptan responders. Pooled analysis of MOMENTUM and INTERCEPT indicates that AXS-07 was effective at acutely treating migraine with a favorable tolerability profile.
- Nurtec (riluzole sublingual) / Biohaven, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Nurtec ODT (rimegepant ODT) / Pfizer
Assessment and management of post-concussive headaches in rugby players: A case Study () - Jun 18, 2024 - Abstract #AHS2024AHS_330;
At follow up he was given Gabapentin, sphenopalatine ganglion block, Nurtec, Botox injections (occipital nerve block). Identification of post-traumatic headaches in patients with a history of concussions is necessary to reduce severity and frequency of headaches.
- lorazepam / Generic mfg., prochlorperazine maleate / Generic mfg., sumatriptan succinate / Generic mfg.
Assessing the relative utility of two headache "rescue rooms" and their respective treatment protocols () - Jun 18, 2024 - Abstract #AHS2024AHS_329;
An outpatient headache "rescue room" represents an attractive option for patients requiring treatment of acute migraine headache, conveying clinical efficacy, decreased ER utilization, and a high degree of patient satisfaction. Dropderidol IM appears to be a particularly safe, effective and efficient treatment for use in this setting.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
A retrospective case series of cervical spinal cord stimulator trials in refractory chronic headache disorders () - Jun 18, 2024 - Abstract #AHS2024AHS_328;
Implantation of cSCS was considered only when numerous pharmacologic and less invasive procedural interventions had been exhausted. It remains unclear which subgroups of patients with chronic refractory headache disorders may benefit most from this intervention.
- memantine / Generic mfg.
A retrospective analysis of the use of memantine for migraine prevention in adolescents () - Jun 18, 2024 - Abstract #AHS2024AHS_327;
These results suggest that memantine is an effective prophylactic treatment option in pediatric patients with headache, especially those with chronic migraine. While this is a retrospective analysis of prophylactic use of memantine in children with chronic headache disorders, prospective studies should be performed to further explore its effects and benefits.
- Evosyal (prabotulinumtoxin A) / Daewoong Pharma, AEON Biopharma
A new injection paradigm of prabotulinumtoxinA for episodic and chronic migraine () - Jun 18, 2024 - Abstract #AHS2024AHS_326;
P2
While this is a retrospective analysis of prophylactic use of memantine in children with chronic headache disorders, prospective studies should be performed to further explore its effects and benefits. Medical professionals with experience in administering injections of both onabotulinumtoxinA in the PREEMPT paradigm (31
- amitriptyline / Generic mfg.
A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: A randomized double-blind clinical trial () - Jun 18, 2024 - Abstract #AHS2024AHS_323;
Both medications are effective in ameliorating migraine headaches and related disabilities. However, amitriptyline appears be a preferable option over cinnarizine, given its faster onset of action, efficacy in reducing headache duration and longer-lasting effects.
- NIH HEAL Initiative Preclinical Screening Platform for Pain program () - Jun 18, 2024 - Abstract #AHS2024AHS_298;
However, amitriptyline appears be a preferable option over cinnarizine, given its faster onset of action, efficacy in reducing headache duration and longer-lasting effects. (PGI), carbamazepine (3
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Understanding the real-world treatment patterns in patients using migraine preventive medications in Ontario, Canada () - Jun 18, 2024 - Abstract #AHS2024AHS_292;
Of those currently using MPMs, 76% are not optimally managed. Further efforts are needed to improve persistence and optimally manage patients.